| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $0 | — | -100.0% |
| R&D Expense | $5.1M | — | +6.2% |
| SG&A Expense | $3.0M | — | +24.9% |
| Operating Income | -$8.1M | — | -52.9% |
| Net Income | -$8.0M | — | -62.7% |
| EPS (Basic) | -$0.86 | — | -53.6% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $7.9M | -3.6% | -24.4% |
| Short-term Investments | $5.0M | -60.5% | -79.9% |
| Current Assets | $15.1M | -33.9% | -60.8% |
| Total Assets | $15.1M | -33.9% | -60.8% |
| Total Liabilities | $4.5M | -3.4% | +14.1% |
| Stockholders' Equity | $10.6M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$8.0M | — | -105.9% |
| Investing Cash Flow | $7.7M | — | +42.9% |
| Financing Cash Flow | $14K | — | — |
| -69.3% |